ReviewVeterinary parasitology2021
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.
Open access · greenAbstract readReview
In one paragraph
Review in Veterinary parasitology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- High Seroprevalence Rates of Toxoplasma gondii and Neospora caninum in Dogs in the Pantanal Region of Mato Grosso, Brazil.Acta parasitologica · 2026Article
- Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Dose-dependent tissue tropism and efficacy of early BKI-1748 treatment in chronicFood and waterborne parasitology · 2025Article
- Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1.PLoS neglected tropical diseases · 2025Article
- Bumped Kinase Inhibitors Inhibit bothACS infectious diseases · 2025Article
- Calcium-dependent protein kinases 2A involved in the growth of both asexual and sexual stages of Cryptosporidium parvum.PLoS neglected tropical diseases · 2025Article
- Molecular pathogenesis of Cryptosporidium and advancements in therapeutic interventions.Parasite (Paris, France) · 2025Review
- Proteome changes duringFrontiers in cellular and infection microbiology · 2025Article
- Single and combination treatment of Toxoplasma gondii infections with a bumped kinase inhibitor and artemisone in vitro and with artemiside in experimentally infected mice.Experimental parasitology · 2023Article
- Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: A comprehensive review.Frontiers in cellular and infection microbiology · 2023Review
- Cryptosporidiosis: From Prevention to Treatment, a Narrative Review.Microorganisms · 2022Review
- Diagnosis and control of cryptosporidiosis in farm animals.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Review
- An update onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Review
- Repurposing the Kinase Inhibitor Mavelertinib for Giardiasis Therapy.Antimicrobial agents and chemotherapy · 2022Article
- Vaccine-Linked Chemotherapy Approach: Additive Effects of Combining theFrontiers in veterinary science · 2022Article
- Characterization of Calcium-Dependent Protein Kinase 2A, a Potential Drug Target Against Cryptosporidiosis.Frontiers in microbiology · 2022Article
- Establishment of a Newborn Lamb Gut-Loop Model to Evaluate New Methods of Enteric Disease Control and Reduce Experimental Animal Use.Veterinary sciences · 2021Article
- CDPKs: The critical decoders of calcium signal at various stages of malaria parasite development.Computational and structural biotechnology journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 3 countries.
Wesley C Van VoorhisCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98109, USA. Electronic address: wesley@uw.edu.
Matthew A HulversonCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98109, USA.
Ryan ChoiCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98109, USA.
Wenlin HuangDepartment of Biochemistry, University of Washington, Seattle, WA, 98195, USA.
Samuel L M ArnoldCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98109, USA.
Deborah A SchaeferSchool of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ, 85721, USA.
Dana P BetzerSchool of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ, 85721, USA.
Rama S R VidadalaDepartment of Chemistry, University of Washington, Seattle, WA, 98195, USA.
Sangun LeeDepartment of Infectious Disease and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, 01536, USA.
Grant R WhitmanCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98109, USA.
Lynn K BarrettCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98109, USA.
Dustin J MalyDepartment of Chemistry, University of Washington, Seattle, WA, 98195, USA.
Michael W RiggsSchool of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ, 85721, USA.
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, WA, 98195, USA.
Thomas J KennedyEleven Bravo LLC, Westport, WI, 53597, USA.
Saul TziporiDepartment of Infectious Disease and Global Health, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA, 01536, USA.
J Stone DoggettOregon Health & Science University, Portland, OR, 97239, USA.
Pablo WinzerInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Nicoleta AnghelInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Dennis ImhofInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Joachim MüllerInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Andrew HemphillInstitute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
Ignacio FerreSaluvet, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, 28040, Madrid, Spain.
Roberto Sanchez-SanchezSaluvet, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, 28040, Madrid, Spain.
Luis Miguel Ortega-MoraSaluvet, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, 28040, Madrid, Spain.
Kayode K OjoCenter for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 98109, USA.
University of Washington · USUniversity of Bern · CHUniversidad Complutense de Madrid · ESUniversity of Arizona · USTufts University · USOregon Health & Science University · US
Funding
Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4MCalcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0MGenetic Analysis of CryptosporidiumR01AI112427 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI STRIEPEN, BORIS · 2014 to 2023
$4.2MOptimization of Lead BKIs for Cryptosporidiosis TherapyR01AI155412 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$4.1MDual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9MGenetic Analysis of CryptosporidiumR37AI112427 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BORIS STRIEPEN · 2024 to 2026
$1.5MCoformulation of bumped kinase inhibitors with Artemisinin combination therapy will stop widespread transmission of artemisinin-resistant malaria strainsR21AI123690 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2017 to 2018
$490kNovel Therapeutic Strategies for ELQ-422, a preclinical Toxoplasmosis Drug CandidateI01BX004522 · VA · PORTLAND VA MEDICAL CENTER · PI Joseph Stone Doggett · 2019 to 2026
–BLRD VA I01 BX004522NIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NIAID NIH HHS R01 AI112427NIAID NIH HHS R01 AI155412NIAID NIH HHS R21 AI123690NIAID NIH HHS R37 AI112427NICHD NIH HHS R01 HD080670
Abstract
This is a review of the development of bumped-kinase inhibitors (BKIs) for the therapy of One Health parasitic apicomplexan diseases. Many apicomplexan infections are shared between humans and livestock, such as cryptosporidiosis and toxoplasmosis, as well as livestock only diseases such as neosporosis. We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora caninum). We discuss the potential uses of BKIs for the treatment of diseases caused by apicomplexan parasites in animals and humans, and the improvements that need to be made to further develop BKIs.
Indexed as
One HealthAnimalsAntiparasitic AgentsApicomplexaCryptosporidiosisHumansPiperidinesPyrimidinesQuinolinesAntiparasitic AgentsBKI 1369PiperidinesPyrimidinesQuinolinesAntiparasticsApicomplexaKinase inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.